Novo Nordisk Shares Rise Amid GLP-1 Competition Amid Viking's Mixed Results

Wednesday, Aug 20, 2025 10:51 am ET1min read

Novo Nordisk's stock price rose by 0.74%, while Viking Therapeutics' shares fell after mixed results from their GLP-1 weight loss pill, VK2735. Novo Nordisk's robust product lineup, partnerships, and FDA approvals enhance its market presence. The company's valuation is significantly undervalued, making it an attractive growth stock within the large growth style box.

Novo Nordisk Shares Rise Amid GLP-1 Competition Amid Viking's Mixed Results

Comments



Add a public comment...
No comments

No comments yet